RISPERDAL CONSTA® (risperidone)
The only FDA-approved, long-acting injectable atypical antipsychotic indicated for the maintenance treatment of Bipolar I Disorder as monotherapy
Helping to provide predictability*† for more of your adult patients with Bipolar I Disorder when administered every 2 weeks.1
†While no medication can guarantee adherence, using a long-acting professionally administered medication can help you recognize a missed
dose and intervene.